SNY Stock Analysis: Buy, Sell, or Hold?
SNY - Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
$42.77
0.05 (0.12%)
▲
5d:
-3.52%
30d:
-2.15%
90d:
-3.04%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 30, 2026
Get Alerted When SNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SNY shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SNY shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$62.36
Based on 6.0% avg growth
INTRINSIC VALUE TODAY
$38.72
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNY is currently trading at $42.77, which is considered oversold relative to its 30-day fair value range of $43.07 to $45.16. The stock's valuation (Forward PE: 7.9) is in line with its historical norms (8.6). Remarkably, the market is currently pricing in an annual earnings decline of 2.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SNY is showing sideways momentum. The price is currently testing key support at $42.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNY scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $53.72 (+25.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNY is showing sideways momentum. The price is currently testing key support at $42.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: SNY scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $53.72 (+25.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$43.07 -
$45.16
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.6% below Wall St target ($53.72)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$43.07 -
$45.16
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$42.41
Resistance Level
$45.23
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.89
Wall Street Target
$53.72
(+25.6%)
Revenue Growth (YoY)
14.6%
Earnings Growth (YoY)
-91.2%
Profit Margin
8.1%
Valuation Discount vs History
-2.9% cheaper
PE vs Historical
7.9 vs 8.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.9%
(market-implied from PE analysis)
1-Year Target
$41.53
(-3%)
2-Year Target
$40.33
(-6%)
3-Year Target
$39.16
(-9%)
3-Yr Target (if PE normalizes)
(PE: 8→9)
$42.68
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 8.0%)
$137.92
(+223%)
Base:
(SPY PE: 7.9, Growth: 8.0%)
$53.95
(+26%)
Bear:
(PE: 6.7, Growth: 8.0%)
$45.85
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 22.72 | Current EPS (TTM): $1.88
Bull Case
$93.98
(+120%)
Analyst growth 100.0%, PE expands to 25.0
Base Case
$85.44
(+100%)
Market implied 100.0%, PE stable at 22.7
Bear Case
$29.05
(-32%)
Severe decline -20.0%, PE contracts to 19.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.9 to 8.6
Stabilization Target:
$46.62
(+9.0%)
PE Expansion Potential:
+9.0%
Share & Embed Analysis
Last updated: September 13, 2026 9:31 AM ET
Data refreshes hourly during market hours. Next update: 10:31 AM
Data refreshes hourly during market hours. Next update: 10:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1319 | 47 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 44 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 53 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$237 | 47 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$388 | 43 HOLD |
